Analysis of the association of diabetes mellitus with cancer using autopsy records
- Authors:
- Ryuichi Wada
- Sotai Kimura
- Shoko Kure
- Kousuke Ishino
- Mitsuhiro Kudo
- Zenya Naito
View Affiliations
Affiliations: Department of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo 113-8602, Japan, Faculty of Medicine, Hirosaki University School of Medicine, Hirosaki 036-8601, Japan
- Published online on: May 19, 2020 https://doi.org/10.3892/wasj.2020.52
-
Article Number:
11
-
Copyright: © Wada
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
In the present study, the association of diabetes mellitus (DM) with cancer was investigated using autopsy records. Among the 83,829 autopsy records between the years 2005 and 2009, 74,869 cases ≥40 years were eligible for the analysis. The cases with DM and cancers were selected, and the risk of cancer was estimated as the odds ratio (OR) by logistic regression analysis with the adjustment of age. Among the 74,869 cases, there were 49,676 males and 25,193 females. DM was noted in 4,901 males (9.9%) and 2,066 females (8.2%). In the liver, the OR for hepatocellular carcinoma (HCC) was increased to 1.25 (95% confidence interval (CI), 1.12-1.39, P<0.001) and to 1.22 (95% CI, 1.00-1.49, P<0.05) in males and females with DM, respectively. The ORs for invasive ductal carcinoma of the pancreas, cancers of the thyroid and kidney were not increased, and the ORs for cancers of the lung, stomach, colon/rectum, biliary tract, prostate, breast and uterus appeared to be decreased. The analyzed autopsy cases corresponded to only 1.4% of deceased individuals aged ≥40 years, and the ORs for cancers in DM estimated using the autopsy records may warrant a careful consideration. To the best of our knowledge, the present study is the first to confirm the increased OR for HCC in DM by a cross-sectional analysis using autopsy records.
View References
|
1
|
Giovannucci E, Harlan DM, Archer MC,
Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG and
Ye D: Diabetes and cancer: A consensus report. Diabetes Care.
33:1674–1685. 2010.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kasuga M, Ueki K, Tajima N, Noda M, Ohashi
K, Noto H, Goto A, Ogawa W, Sakai R, Tsugane S, et al: Report of
the Japan diabetes society/Japanese cancer association joint
committee on diabetes and cancer. Cancer Sci. 104:965–976.
2013.PubMed/NCBI View Article : Google Scholar
|
|
3
|
El-Serag HB, Hampel H and Javadi F: The
association between diabetes and hepatocellular carcinoma: A
systematic review of epidemiologic evidence. Clin Gastroenterol
Hepatol. 4:369–380. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Huxley R, Ansary-Moghaddam A, Berrington
de González A and Woodward M: Type-II diabetes and pancreatic
cancer: A meta-analysis of 36 studies. Br J Cancer. 92:2076–2083.
2005.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Inoue M, Iwasaki M, Otani T, Sasazuki S,
Noda M and Tsugane S: Diabetes mellitus and the risk of cancer:
Results from a large-scale population-based cohort study in Japan.
Arch Intern Med. 166:1871–1877. 2006.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Khan M, Mori M, Fujino Y, Shibata A,
Sakauchi F, Washio M and Tamakoshi A: Japan Collaborative Cohort
Study G. Site-Specific cancer risk due to diabetes mellitus
history: Evidence from the Japan collaborative cohort (JACC) study.
Asian Pac J Cancer Prev. 7:253–259. 2006.PubMed/NCBI
|
|
7
|
Kuriki K, Hirose K and Tajima K: Diabetes
and cancer risk for all and specific sites among Japanese men and
women. Eur J Cancer Prev. 16:83–89. 2007.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Matsuo M: Association between diabetes
mellitus and hepatocellular carcinoma: Results of a hospital- and
community-based case-control study. Kurume Med J. 50:91–98.
2003.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Japanese Society of Pathology: Annual
report of pathological autopsy cases in Japan 2005-2009. Japanese
Society of Pathology, Tokyo, 2006-2010.
|
|
10
|
Japanese Ministry of Health Labour and
Welfare: Vital statistics of Japan final data. General Mortality,
2009. https://www.e-stat.go.jp/.
|
|
11
|
Jing W, Jin G, Zhou X, Zhou Y, Zhang Y,
Shao C, Liu R and Hu X: Diabetes mellitus and increased risk of
cholangiocarcinoma: A meta-analysis. Eur J Cancer Prev. 21:24–31.
2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Japanese Ministry of Health Labour and
Welfare: The national health and nutrition survey in Japan, 2007.
https://www.mhlw.go.jp/bunya/kenkou/eiyou09/01.html.
|
|
13
|
Butler AE, Campbell-Thompson M, Gurlo T,
Dawson DW, Atkinson M and Butler PC: Marked expansion of exocrine
and endocrine pancreas with incretin therapy in humans with
increased exocrine pancreas dysplasia and the potential for
glucagon-producing neuroendocrine tumors. Diabetes. 62:2595–2604.
2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Harja E, Lord J and Skyler JS: An analysis
of characteristics of subjects examined for incretin effects on
pancreatic pathology. Diabetes Technol Ther. 15:609–618.
2013.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Giorda CB, Picariello R, Tartaglino B,
Nada E, Costa G and Gnavi R: Incretin-based therapy and risk of
cholangiocarcinoma: A nested case-control study in a population of
subjects with type 2 diabetes. Acta Diabetol. 57:401–408.
2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Goda M and Kadowaki T: Teneligliptin for
the treatment of type 2 diabetes. Drugs Today (Barc). 49:615–629.
2013.PubMed/NCBI View Article : Google Scholar
|
